The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium) is a technically focused, cross functional organization with a mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators, and the broader research and development community. The IQ Consortium was formed in 2009 and is made up of more than 35 pharmaceutical and biotechnology companies engaged in innovative research and development. The IQ Clinical Pharmacology Leadership Group (CPLG) was established in 2011, and currently includes 13 Working Groups including Japan subteam formed in 2019. The CPLG's mission is to address themes of experimental design, analysis, translational sciences, and the integration of nonclinical and clinical data to enable dosing and labeling recommendations. It also provides scientific counsel to the pharmaceutical industry, regulatory authorities, and academia. The dissemination of best practices and knowledge sharing is also achieved through benchmarking surveys, webinars, publications, public presentations, and discussion groups. IQ CPLG has interacted a lot with regulatory authorities including FDA, EMA and PMDA so far to provide industrial perspective and comments to them. This poster session will introduce the mission and activities of IQ CPLG in parallel with the presentation regarding "New Modalities: Cell and Gene Therapies" and "Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology" at the symposium and the educational seminar in JSCPT 2021.